Tune in to hear primary care physician and endocrinologist Dr. Rozalina G. McCoy discuss how we can talk to our diabetes patients about hypoglycemia and what we need to consider when treating older patients who are experiencing hypoglycemia emergency.

Ms. Deborah Hinnen, an advanced practice nurse and certified diabetes educator at the University of Colorado Health in Colorado Springs sits down with Dr. Charles Turck to discuss hypoglycemia risk factors and treatment protocols according to the ADA guidelines.

Dr. Charles Turck discusses the pervasiveness of hypoglycemia in adults with type 2 diabetes with Dr. Brian Frier, an Honorary Professor of Diabetes at the University of Edinburgh.

Dr. Jason Ng, Clinical Lead of the Diabetes Technology Medical Home Unit at the University of Pittsburgh, shares strategies we can use to help patients with type 2 diabetes can lower their risk of hypoglycemia.

Dr. Rozalina G. McCoy, an endocrinologist, primary care physician, and a National Institutes of Health-funded health services researcher examines hypoglycemia risk in insulin-treated type 2 diabetic patients and explores strategies to reduce their risk of recurrent hypoglycemia.

When treating type 1 diabetes, should we be focusing on disease prevention rather than reversal? Dr. John Anderson takes a look at prevention tactics for type 1 diabetes progression with Dr. Raghu Mirmira, a Professor of Medicine and the Director of the Translational Research Center at the University of Chicago.

Experts in the immunopathology of type 1 diabetes discuss the epidemiology, non-genetic and genetic risk factors, and progression from preclinical to clinical stages of this disease. The discussion will emphasize the breakdown of immune tolerance that precedes type 1 diabetes and the subsequent pathogenetic role of islet autoantibodies responsible for its clinical manifestations.

How is technology like continuous glucose monitors impacting the way we care for patients with diabetes, especially amid the COVID-19 pandemic? To learn more about the technological advancements in diabetes care, Dr. Carol Wysham speaks with Dr. Irl Hirsch, a Professor in Diabetes Treatment and Teaching Chair at the University of Washington School of Medicine in Seattle, Washington.

Why was there so much discordance between some patients’ GMI and their measured A1C? That’s the exact question Dr. Irl Hirsch from the University of Washington School of Medicine asked and explored in a paper he recently co-authored. And now Dr. Hirsch is here to share his findings.

SGLT-2 inhibitors have been authorized for diabetic patients in Europe, but is it close to receiving FDA approval in the U.S.? Dr. Anne Peters of USC speaks with Dr. John Buse about SGLT-2 inhibitors and considerations for diabetic ketoacidosis, heart failure, and chronic kidney disease.